|
TIPO has fully implemented the WIPO standard ST.26 from August 1, 2022. All nucleotide and/or amino acid sequences presented in invention patent applications must comply with the new Standard.
Main points and transition period:
- Transition period: TIPO accepts all applications between July 1 and 31, 2022, even if the disclosed sequences do not comply with the new Standard.
- After August 1, 2022, if application does not meet the requirements of the new Standard, TIPO will issue an Office Action to require the applicant to file a new sequence listing compliant with the WIPO standard ST.26 within a time limit.
*If the substantial content of supplement sequence listing is the same as the original filed one, the application date will not be effected/delayed.
- If the priority application filed with WIPO standard ST.25, the later application filed after August 1, 2022 cannot continue using the sequence listing in accordance with WIPO standard ST.25.
- Divisional applications filed after August 1, 2022 disclosing amino acid and nucleotide sequences are allowed to carry over the sequence listing with WIPO standard ST.25 from the parent application.
Software materials:
- WIPO Sequence
- WIPO Sequence Validator
|
